BioMark Diagnostics Inc. reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was CAD 0.036889 million compared to CAD 0.019818 million a year ago. Net loss was CAD 0.393698 million compared to CAD 0.256879 million a year ago.
For the nine months, sales was CAD 0.113746 million compared to CAD 0.019818 million a year ago. Net loss was CAD 1.34 million compared to CAD 0.724031 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.01 a year ago.